Paul George to Join Venus Williams, Frances Tiafoe and Taylor Fritz in Partnering with BetterHelp to Give Away Up to $3M in Free Therapy

BetterHelp, the world’s largest and leading mental health therapy platform, is teaming up with NBA star Paul George to destigmatize mental health and provide up to $3 million worth of free therapy to people in need. George is the latest star athlete to speak out about mental health and partner with BetterHelp, joining a growing roster of pro-athletes that includes tennis superstars Venus Williams, Frances Tiafoe, and Taylor Fritz.

Paul George, nicknamed “PG-13,” is one of the most dynamic and popular professional basketball players in the National Basketball Association, where he stars for the Los Angeles Clippers. He is a seven-time NBA All-Star and six-time member of the All-NBA team, as well as an Olympic Gold Medalist. He has spoken openly and courageously about his own struggles with anxiety and depression during the pandemic, and the importance of prioritising mental wellness in addition to physical strength, in order to inspire others to take care of their own, and their loved ones, mental well-being.

“Mental Health is just as important as physical health to me. I can be in the best physical shape of my life but if my mental health is lacking, it won’t make a difference,” said Paul George. “Getting help to better yourself mentally has been extremely important in my life and has allowed me to be the player, father, husband and person I am today. This is why I am so excited to partner with BetterHelp to provide access to free therapy and help raise mental health awareness around the world and specifically in my hometown of Palmdale.”

The giveaway, offered by BetterHelp to new users who sign up at https://www.betterhelp.com/paulgeorge, will come in the form of one-month free therapy membership, with a total equivalent value of up to $3 million. As part of the partnership, BetterHelp would also support Paul George’s Foundation’s Charity Event: PG13 Topgolf Classic in November. More details to come.

“Everyone — even pro athletes — can struggle with mental health issues,” said Alon Matas, President and Founder of BetterHelp. “We’re teaming up with incredible athletes like Paul George to remind people to take care of themselves, and we’re providing them with the resources to get started.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”